$4.69
+2.18%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.55
From 52W high−6.94%
Volume892255.00
Market cap$681.88M
P/E (TTM)—
P/S (TTM)17.7x
Div yield—
Key dataOct 19, 2026
Open
$4.55
From 52W high
−6.94%
Volume
892255.00
Market cap
$681.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−32.4x
P/E (TTM)
—
RSI (14)
53.0
MomentumView details →
1D Return
+2.18%
YTD Return
+153.29%
SummaryUpdated Jun 1, 2026
OmniAb, Inc. (NASDAQ:OABI) is a biotechnology company founded in 2012 and headquartered in Emeryville, California. The company went public in September 2021 and operates as a platform provider for therapeutic antibody discovery technologies. OmniAb has developed a unique business model centered around genetically modified transgenic animals that produce human-like antibodies, which pharmaceutical and biotechnology companies use to develop new therapeutic drugs. The company has grown from serving 69 partners in 2022 to 95 active partners as of early 2025, with over 375 active programs in its pipeline.
Similar companies
Latest newsMore news →
OmniAb announced that it will report financial results for the three and nine months ended September 30, 2026, before U.S. markets open on October 30, 2026, and hold a conference call at 8:00 a.m. Eastern time that day.5d agoOmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.64d ago